Gain of antitumor functions and induction of differentiation in cancer stem cells contribute to complete cure and no relapse

Critical Reviews in Oncogenesis

Volumn 15, Issue 1-2, 2009, Pages 57-78

  Garg, Minal ^a  

^a UNIVERSITY OF LUCKNOW   (India)

Author keywords

Apoptosis; Cancer stem cells; Differentiation therapy; Stem cell markers; Tumor suppression

Indexed keywords

1,4 DIHYDRO 2,4,6 TRIMETHYL 3,5 PYRIDINEDICARBOXYLIC ACID DIETHYL ESTER; ABC TRANSPORTER; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BMI1 PROTEIN; BONE MORPHOGENETIC PROTEIN; BREAST CANCER RESISTANCE PROTEIN; BUCLADESINE; CELL ADHESION MOLECULE; CELL SURFACE MARKER; CHEMOKINE RECEPTOR CXCR4; CISPLATIN; CYCLOPAMINE; CYTARABINE; GAP JUNCTION PROTEIN; GROWTH FACTOR; IMATINIB; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAPAMYCIN; RETINOIC ACID; SALINOSPORAMIDE A; SONIC HEDGEHOG PROTEIN; SORAFENIB; SULINDAC SULFONE; TANESPIMYCIN; TELOMERASE; TELOMERASE INHIBITOR; TRANSCRIPTION FACTOR; WNT PROTEIN; ZOSUQUIDAR; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL GROWTH; CELL HOMING; CELL POPULATION; CELL RENEWAL; CELL TRANSFORMATION; CLINICAL TRIAL; DISEASE CONTROL; DISEASE FREE SURVIVAL; DNA REPAIR; DRUG TRANSPORT; HEMATOPOIETIC STEM CELL; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RELAPSE; REVIEW; STEM CELL; ANIMAL; DRUG EFFECT; NEOPLASM; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION;

EID: 75949104197     PISSN: 08939675     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevoncog.v15.i1-2.30     Document Type: Review

References (90)

1. Gurdon JB. The de velopmental capacity of nuclei taken from intestinal epithelial cells of feeding tadpoles. J Embryol Exp Morphol. 1962; 10:622-640.
2. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, Fuhlbrigge RC, Kupper TS, Sayegh MH, Frank MH. Identification of cells initiating human melanomas. Nature. 2008;451(7176):345-349
3. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature. 2008;456(7222):593-598
4. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H, Morrison SJ. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature. 2006;441(7092):475-482 (Pubitemid 44050144)
5. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature. 2004;432(7015):324-331
6. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434(7035):843-850 (Pubitemid 40558990)
7. Mimeault M, Brand RE, Sasson AA, Batra SK Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas. 2005;31(4):301-316
8. Yu HM, Frank DE, Zhang J, You X, Carter WG, Knudsen BS. Basal prostate epithelial cells stimulate the migration of prostate cancer cells. Mol Carcinogenesis. 2004;41(2):85-97.
9. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4(7):540-550
10. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4(1):71-78
11. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6(5):392-401.
12. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer. 2001;1(1):46-54.
13. Munshi HG, Stack MS. Reciprocal interactions between adhesion receptor signaling and MMP regulation. Cancer Metastasis Rev. 2006;25(1):45-56.
14. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006;25(1):9-34.
15. Bergers G, Coussens LM. Extrinsic regulators of epithelial tumor progression: metalloproteinases. Curr Opin Genet Dev. 2000;10(1):120-127
16. Li M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med. 2006;231(1):20-27
17. Loberg RD, Day LL, Harwood J, Ying C, St John LN, Giles R, Neeley CK, Pienta KJ. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia. 2006;8(7):578-586
18. Mimeault M, Batra SK. Functions of tumorigenic and migrating cancer progenitor cells in cancer progression and metastasis and their therapeutic implications. Cancer Metastasis Rev. 2007;26(1):203-214
19. Krivtsov KV, Twomey D, Feng Z, Stubbs M, Wang Y, Faber J, Levine JE, Wang J, Hahn WC, Gilliland DG, Golub TR, Armstrong SA. Transformation from committed progenitor to leukemia stem cell initiated by MLL-AF9. Nature. 2006;442(7104):818-822.
20. Pan CX, Zhu W, Cheng L. Implications of cancer stem cells in the treatment of cancer. Future Oncol. 2006;2(6):723-731
21. Moorem KA, Lemischka IR. Stem cells and their niches. Science. 2006;311(5769):1880-1885
22. Lee CJ, Dosch J, Simeone DM. Pancreatic cancer stem cells. J Clin Oncol. 2008;26(17):2806-2812
23. Natarajan TG, FitzGerald KT. Markers in normal and cancer stem cells. Cancer Biomarkers. 2007;3:211-231.
24. Schroeder JA, Adriance MC, McConnell EJ, Thompson MC, Pockaj B, Gendler SJ. ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas. J Biol Chem. 2002;277(25):22692-22698
25. Rye PD, Stigbrand T. Interfering with cancer: a brief outline of advances in RNA interference in oncology. Tumour Biol. 2004;25(5-6):329-336
26. Burger AM. Highlights in experimental therapeutics. Cancer Lett. 2004 ; 245, 11-21.
27. Almeida GM, Duarte TL, Farmer PB, Steward WP, Jones GD. Multiple end-point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: implications for predictive testing. Int J Cancer. 2008;122(8):1810-1819
28. Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT, Berman DM, Beachy PA. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature. 2004;431(7009):707-712
29. Mao L, Xia YP, Zhou YN, Dai RL, Yang X, Duan SJ, Qiao X, Mei YW, Hu B, Cui H. A critical role of Sonic Hedgehog signaling in maintaining the tumorigenicity of neuroblastoma cells. Cancer Sci. 2009;100(10):1848-1855
30. Chen X, Horiuchi A, Kikuchi N, Osada R, Yoshida J, Shiozawa T et al. Hedgehog signal pathway is activated in ovarian carcinomas, correlating with cell proliferation: it's inhibition leads to growth suppression and apoptosis. Cancer Sci. 2007;98(1):68-76.
31. Apte U, Thompson MD, Cui S, Liu B, Cieply B, Monga SP. Wnt/beta-catenin signaling mediates oval cell response in rodents. Hepatology. 2008;47(1):288-295
32. Galmozzi E, Facchetti F, La Porta CA. Cancer stem cells and therapeutic perspectives. Curr Med Chem. 2006;13(6):603-607
33. Chumsri S, Phatak P, Edelman MJ, Khakpour N, Hamburger AW, Burger AM. Cancer stem cells and individualized therapy. Cancer Genomics Proteomics. 2007;4(3):165-174
34. Récher C, Dos Santos C, Demur C, Payrastre B. mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle. 2005;4(11):1540-1549
35. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H, et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature. 2006;441(7092):475-482 (Pubitemid 44050144)
36. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98(8):2301-2307
37. Mueller MT, Hermann PC, Witthauer J, Rubio-Viqueira B, Leicht SF, Huber S, Ellwart JW, Mustafa M, Bartenstein P, D'Haese JG, Schoenberg MH, Berger F, Jauch KW, Hidalgo M, Heeschen C. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology. 2009;137(3):1102-1113
38. Sandler A, Gordon M, De Alwis DP, Pouliquen I, Green L, Marder P, et al. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin Cancer Res. 2004;10(10):3265-3272
39. Pan CX, Zhu W, Cheng L. Implications of cancer stem cells in the treatment of cancer. Future Oncol. 2006;2(6):723-731
40. Jin Y, Bin ZQ, Qiang H, Liang C, Hua C, Jun D, Dong WA, Qing L. ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma. J Cancer Res Clin Oncol. 2009;135(10):1369- 1376
41. Radujkovic A, Schad M, Topaly J, Veldwijk MR, Laufs S, Schultheis BS, Jauch A, Melo JV, Fruehauf S, Zeller WJ. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG. Leukemia. 2005;19(7):1198-1206
42. Hope KJ, Jin L, Dick JE. Human acute myeloid leukemia stem cells. Arch Med Res. 2003;34(6):507-514
43. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006;12(10):1167-1174 (Pubitemid 44527352)
44. Rajasagi M, von Au A, Singh R, Hartmann N, Zöller M, Marhaba R. Anti-CD44 induces apoptosis in T lymphoma via mitochondrial depolarization. J Cell Mol Med. 2009. (To be print).
45. Kucia M, Reca R, Miekus K, Wanzeckm J, Wojakowskim W, Janowska-Wieczorek, et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 2005;23(7):879-894
46. Burger JA, Bürkle A. The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol. 2007;137(4): 288-296
47. Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res. 2007 Apr 15;67(8):3560-3564
48. Sheu CC, Yu YP, Tsai JR, Chang MY, Lin SR, Hwang JJ, Chong IW. Development of a membrane array-based multimarker assay for detection of circulating cancer cells in patients with non-small cell lung cancer. Int J Cancer. 2006;119(6):1419-1426
49. Burdon RH. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med. 1995;18(4):775-794
50. Sauer H, Wartenberg M, Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem. 2001;11(4):173-186
51. Smith J, Ladi E, Mayer-Proschel M, Noble M. Redox state is a central modulator of the balance between self-renewal and differentiation in a dividing glial precursor cell. Proc Natl Acad Sci U S A. 2001;97(18):10032-10037
52. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009;8(7):579-591
53. Samudio I, Kurinna S, Ruvolo P, Korchin B, Kantarjian H, Beran M, Dunner K Jr, Kondo S, Andreeff M, Konopleva M. Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells. Mol Cancer Ther. 2008;7(5):1130-1139
54. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, Paz B, Shen J, Lau SK, Quake SR, Brown JM, Weissman IL, Clarke MF. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458(7239):780-783
55. Tang C, Chua CL, Ang BT. Insights into the cancer stem cell model of glioma tumorigenesis. Ann Acad Med Singapore. 2007;36(5):352-357
56. Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol. 2008;26(17):2839-2845
57. Kutuk O, Letai A. Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res. 2008;68(19):7985-7994
58. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10(5):375-388
59. Aneja R, Liu M, Yates C, Gao J, Dong X, Zhou B, Vangapandu SN, Zhou J, Joshi HC. Multidrug resistance-associated protein-overexpressing teniposide-resistant human lymphomas undergo apoptosis by a tubulin-binding agent. Cancer Res. 2008;68(5):1495-1503
60. Baritaki S, Suzuki E, Umezawa K, Spandidos DA, Berenson J, Daniels TR, et al. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAILenhanced apoptosis in cancer cells. J Immunol. 2008;180(9):6199-6210
61. Zhang W, Konopleva M, Ruvolo VR, McQueen T, Evans RL, Bornmann WG, et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia. 2008;22(4):808-818
62. Basile LA, Gallaher TK, Shibata D, Miller JD, Douer D. Multilineage hematopoietic recovery with concomitant antitumor effects using low dose Interleukin-12 in myelosuppressed tumor-bearing mice. J Transl Med. 2008;6:26.
63. Reese JS, Liu L, Gerson SL. Repopulating defect of mismatch repair-deficient hematopoietic stem cells. Blood. 2003;102(5):1626-1633
64. Moreland NJ, Illand M, Kim YT, Paul J, Brown R. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin. Cancer Res. 1999;59(9):2102-2106
65. Wang Y, Qin J. MSH2 and ATR form a signaling module and regulate two branches of the damage response to DNA methylation. Proc Natl Acad Sci U S A. 2003;100(26):15387-15392
66. Hirose Y, Katayama M, Stokoe D, Haas-Kogan DA, Berger MS, Pieper RO. The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Mol Cell Biol. 2003;23(22):8306-8315
67. Garg M. Mismatch repair deficiencies and the origin of cancer stem cells. In: Zänker KS, Dittmar T, editors. Stem Cells and Cancer. Germany: Nova Science Publishers Inc; 2009.
68. Fujita H, Kato J, Horii J, Harada K, Hiraoka S, Shiraha H, et al. Decreased expression of hMLH1 correlates with reduced 5-fluorouracil-mediated apoptosis in colon cancer cells. Oncol Rep. 2007;18(5):1129-1137
69. Duckett DR, Drummond JT, Murchie AI, Reardon JT, Sancar A, Lilley DM, et al. Human Mut S alpha recognizes damaged DNA base pairs containing O6- methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. Proc Natl Acad Sci U S A. 1996;93(13):6443-6447
70. Mello JA, Acharya S, Fishel R, Essigmann JM. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem Biol. 1996;3(7):579-589
71. Mu D, Tursun M, Duckett DR, Drummond JT, Modrich P, Sancar A. Recognition and repair of compound DNA lesions (base damage and mismatch) by human mismatch repair and excision repair systems. Mol Cell Biol. 1997;17(2):760-769
72. Nehmé A, Baskaran R, Aebi S, Fink D, Nebel S, Cenni B, et al. Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Cancer Res. 1997;57(15):3253-3257
73. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG Jr Levrero M, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature. 1999;399(6738):806-809
74. Lan Z, Sever-Chroneos Z, Strobeck MW, Park CH, Baskaran,R, Edelmann W, Leone, G et al. DNA damage invokes mismatch repair-dependent cyclin D1 attenuation and retinoblastoma signaling pathways to inhibit CDK2. J Biol Chem. 2002;277(10):8372-8381
75. Drummond JT, Bellacosa A. Human DNA mismatch repair in vitro operates independently of methylation status at CpG sites. Nucl Acids Res. 2001;29:2234-2243.
76. Samimi G, Fink D, Varki NM, Husain A, Hoskins WJ, Alberts DS, et al. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res. 2000;6(4):1415-1421
77. Watanabe Y, Koi M, Hemmi H, Hoshai H, Noda K. A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer. Br J Cancer. 2001;85(7):1064-1069
78. Shiraishi A, Sakumi K, Sekiguchi M. Increased susceptibility to chemotherapeutic alkylating agents of mice deficient in DNA repair methyltransferase. Carcinogenesis. 2000;21(10):1879-1883
79. Vaish M. Mismatch repair deficiencies transforming stem cells into cancer stem cells and therapeutic implications. Mol Cancer. 2007;6:26.
80. Abuin A, Zhang H, Bradley A. Genetic analysis of mouse embryonic stem cells bearing Msh3 and Msh2 single and compound mutations. Mol Cell Biol. 2000;20(1):149-157
81. Grover A, Adamson ED. Evidence for the existence of an early common biochemical pathway in the differentiation of F9 cells into visceral or parietal endoderm: modulation by cyclic AMP. Dev Biol. 1986;114:492-503.
82. Spira AL, Carducci MA. Differentiation therapy. Curr Opin.Pharmacol. 2003;3:338-343.
83. Mehta K. Retinoids are regulators of gene transcription. J Biol Regul Homeost Agents. 2003;17:1-12.
84. Fialkow PJ. Stem cell origin of human myeloid blood cell neoplasms. Verh Dtsch Ges Pathol. 1990;74:43-47
85. Jones LK, Saha V. Philadelphia positive acute lymphoblastic leukaemia of childhood. Br J Haematol. 2005;130(4):489-500.
86. Hochhaus A. Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors. Ann Oncol. 2006;17 Suppl 10: 274-279
87. Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, Trumpp A. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature. 2009;458(7240):904-908.
88. Ocker M, Alajati A, Ganslmayer M, Zopf S, Lüders M, Neureiter D H, et al. The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Res Clin Oncol. 2005;131(6):385-394
89. Luong QT, O'Kelly J, Braunstein GD, Hershman JM, Koeffler HP. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res. 2006;12(18):5570-5577
90. Yaccoby S, Wezeman MJ, Zangari M, Walker R, Cottler-Fox M, Gaddy D, et al. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica. 2006;91(2):192-199